WallStSmart
ZVRA

Zevra Therapeutics Inc.

NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY

$9.67
-2.32% today

Updated 2026-04-29

Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
52W range
$7 – $13
Volume
1.1M

Zevra Therapeutics Inc. (ZVRA) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+54.7%
Last 4 quarters
Revenue YoY growth
+183.4%
Most recent quarter
EPS YoY growth
+127.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-7.5%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-7.9%
2026-03-11
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-11$0.19+280.0%$11.06$10.19-7.9%
2025-11-05$-0.01+66.7%$9.79$9.09-7.2%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.05$0.19+280.0%$34.13M+183.4%
2025-09-30$-0.03$-0.01+66.7%$26.06M+605.4%
2025-06-30$2.19$-0.06-102.7%$25.88M+481.7%
2025-03-31$-0.18$-0.06+66.9%$20.40M+495.6%
2024-12-31$-0.40$-0.69-73.1%$12.04M
2024-09-30$-0.42$-0.69-64.3%$3.69M+27.6%
2024-06-30$-0.43$-0.48-11.6%$4.45M-47.5%
2024-03-31$-0.48$-0.40+16.7%$3.42M+7.8%
2023-12-31$-0.27$-0.40-48.1%
2023-09-30$-0.30$-0.40-33.3%$2.90M
2023-06-30$-0.34$-0.15+55.9%$8.47M
2023-03-31$-0.23$-0.34-47.8%$3.18M

Frequently asked questions

Has Zevra Therapeutics Inc. beaten earnings estimates?
Zevra Therapeutics Inc. has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +54.7% over the last 3 quarters.
How does ZVRA stock react to earnings?
ZVRA stock has moved an average of -7.5% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Zevra Therapeutics Inc.'s revenue growth rate?
Zevra Therapeutics Inc. reported year-over-year revenue growth of +183.4% in its most recent quarter, with EPS growing +127.5% year-over-year.